- Home
- PRLD
as 07-26-2024 4:00pm EST
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 211.5M | IPO Year: | 2020 |
| Target Price: | $5.25 | AVG Volume (30 days): | 172.9K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.66 - $6.72 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Prelude Therapeutics Incorporated News
PRLD Breaking Stock News: Dive into PRLD Ticker-Specific Updates for Smart Investing
Simply Wall St.
12 hours ago
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Clinical Trials Arena
17 days ago
Prelude and MSD partner to trial PRT3789 and Keytruda combination
MT Newswires
18 days ago
Prelude Therapeutics Inks Deal With Merck for Phase 2 Study to Evaluate its SMARCA2 Degrader With Keytruda
GlobeNewswire
18 days ago
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
The Fly
a month ago
Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Compare PRLD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRLD Prelude Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.